Journal
CANCER MANAGEMENT AND RESEARCH
Volume 12, Issue -, Pages 7973-7981Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S268032
Keywords
gastric cancer; signet ring cell; pathology; combined modality therapy
Categories
Funding
- Chinese Academy of Medical Science/Peking Union Medical College [2019-1002-80]
Ask authors/readers for more resources
Recent advances in the epidemiology, pathology, molecular mechanisms, and combined modality therapy (CMT) fields have shown that gastric signet ring cell carcinoma (GSRC) should be considered a distinct cancerous entity. Clinical management of this cancer is challenging, with chemoradioresistance and poor outcomes in advanced stages. Pathological and molecular sets of GSRC demonstrate different features of poor cohesion and differentiation according to the WHO, Japanese Gastric Cancer Association, and Lauren classifications. These features also result in poor response to adjuvant and neoadjuvant chemoradiotherapy. Certain studies of GSRC showed the disputed effectiveness of hyperthermic intraperitoneal chemotherapy and immunotherapy. Our aim was to discuss how an improved understanding of these therapeutic benefits may provide better treatment selection for patients, and therefore improve survival. The challenges in the new understanding of GSRC in routine practice and pathology, and the current limitations of treatment will also be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available